Latest Market Forecasts News

Narryer Metals has uncovered a new scandium-rich project in Western Australia’s Great Southern region, with historic drilling showing promising grades over a 1.7km strike. The Pingrup Project complements its Rocky Gully asset and could position the company as a notable scandium supplier.

Sparc Hydrogen has partnered with US-based SunHydrogen to integrate and test solar-driven green hydrogen modules, hitting a notable 10% solar-to-hydrogen efficiency in early trials. This collaboration aims to advance pilot-scale testing and techno-economic analysis to lower hydrogen production costs.

Osteopore has inked a three-year distribution agreement with Al-Umnia Medical to bring its 3D-printed orthopaedic implants to five Gulf countries, targeting a rapidly expanding regional market.

Avecho Biotechnology has secured a unanimous recommendation to continue its Phase III insomnia trial without increasing sample size, alongside raising $1.9 million through option exercises and bolstering its cash position to $6.6 million.

Green Technology Metals (ASX: GT1) completed an A$11 million recapitalisation, advancing its Seymour Lithium Project DFS, permitting, and financing efforts with a target Final Investment Decision in 2027.

Ovanti appoints two early Afterpay executives to its Advisory Board as it prepares to relaunch its BNPL platforms IOUPAY and myIOU, targeting rapid growth in Southeast Asia and beyond.

Activeport and FirstWave have teamed up to launch an AI Gateway that provides large enterprises and government clients with secure, high-performance access to GPU compute over Australia’s largest carrier networks.

LTR Pharma’s intranasal spray OROFLOW® has secured ethics approval for a clinical study targeting oesophageal motility disorders, marking its first foray beyond erectile dysfunction. The study, led by Dr Peter Wu, aims to validate a non-invasive alternative for swallowing difficulties in a market projected to reach US$8.1 billion by 2034.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

AFT Pharmaceuticals delivered a 22% revenue jump in FY26 to NZD 254.7 million, surpassing profit guidance and expanding its footprint to 87 countries. The company is advancing multiple R&D projects, including a pivotal Phase III injectable iron trial, while targeting over NZD 300 million in revenue for FY27.

Chilwa Minerals’ latest assays from drill hole MPYDD007 at Nakombe South in Malawi confirm a multi-commodity critical minerals system with significant niobium, tantalum, rare earth elements, and gallium mineralisation. The company has defined a maiden conceptual Exploration Target and is advancing drilling towards a maiden Mineral Resource.

dorsaVi has secured exclusive rights to two key robotics patents from NTU Singapore, filling critical gaps in safety control and data acquisition to expand into collaborative robotics and exoskeleton markets.